Literature DB >> 7173308

Pharmacokinetics of pancuronium in man: a linear system.

P Duvaldestin, M Demetriou, A D'Hollander.   

Abstract

Pancuronium in bolus doses of 40 to 350 microgram/kg was administered to surgical patients in order to evaluate the linearity of its pharmacokinetics. The profile of the plasma decay curve and of its urinary elimination were compared with reference to the administered dose. It was possible to superimpose the dose-normalized plasma decay-curves. The parameters of the two compartment-open model used to describe the pharmacokinetics of pancuronium were not influenced by the dose. The elimination half-life was 89 +/- 20 min and the plasma clearance was 1.84 +/- 0.38 ml/min/kg. The profiles of cumulative urinary excretion were also dose-independent. After 6 and 24 h, 57% and 69% of the administered dose, respectively, had been excreted in the urine. The results indicate that the pharmacokinetics of pancuronium is linear.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173308     DOI: 10.1007/bf00613623

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

2.  Linearity and superposition in pharmacokinetics.

Authors:  C D Thron
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

3.  Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials.

Authors:  U W Kersten; D K Meijer; S Agoston
Journal:  Clin Chim Acta       Date:  1973-02-28       Impact factor: 3.786

4.  The fate of pancuronium bromide in man.

Authors:  S Agoston; G A Vermeer; U W Kertsten; D K Meijer
Journal:  Acta Anaesthesiol Scand       Date:  1973       Impact factor: 2.105

5.  Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects.

Authors:  P Duvaldestin; J Saada; J L Berger; A D'Hollander; J M Desmonts
Journal:  Anesthesiology       Date:  1982-01       Impact factor: 7.892

Review 6.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

7.  Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis.

Authors:  P Duvaldestin; D Henzel
Journal:  Br J Anaesth       Date:  1982-05       Impact factor: 9.166

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Pancuronium pharmacokinetics in patients with liver cirrhosis.

Authors:  P Duvaldestin; S Agoston; D Henzel; U W Kersten; J M Desmonts
Journal:  Br J Anaesth       Date:  1978-11       Impact factor: 9.166

10.  Fazadinium and pancuronium: a pharmacodynamic study.

Authors:  C J Hull; M J English; A Sibbald
Journal:  Br J Anaesth       Date:  1980-12       Impact factor: 9.166

View more
  1 in total

1.  Pharmacokinetic and pharmacodynamic modelling with pancuronium.

Authors:  M A Evans; C A Shanks; K F Brown; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.